| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 72.46M | — |
| Operating expense | — | — |
| Net income | -14.35M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, UR8.F returned +139.1% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +100.7% |
| 1 year | +139.1% |
| 5 years | +165.3% |
| All-time high | €51.53 (May 2018) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in UR8.F would be worth today ›No. UroGen Pharma Ltd. has not paid a dividend in the past 12 months.
UroGen Pharma Ltd. is part of the Healthcare sector.
UroGen Pharma Ltd. has a market cap of 1.89B EUR, based on the latest quote.
UroGen Pharma Ltd. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
